The freshwater crabs of West Africa : family Potamonautidae

The area of West Africa covered by this book includes eighteen countries : Mauritania, Senegal, The Gambia, Guinea Bissau, Guinea, Sierra Leone, Liberia, Côte d'Ivoire, Mali, Burkina Faso, Ghana, Togo, Benin, Niger, Nigeria, Chad, Cameroon and Equatorial Guinea (Bioko). Chad, Cameroon and part of Equatorial Guinea (Bioko) are usually treated as part of Central Africa rather than West Africa but these countries have been included because their freshwater crab faunas are principally West African in character (although endemic taxa and other species of Central African origin may also be represented in these countries). The West African faunal region is an informal subdivision of the Afrotropical (Ethiopian) zoogeographical region, and lies to the south of the European and Middle Eastern components of the Palaearctic zoogeographical region, where freshwater crabs of the genus #Potomon (family #Potamidae, Ortmann, 1896) are found. The West African freshwater crab fauna includes at least thrity-two species in seven genera and one family. This fauna is arguably the most diverse in Africa and has a distinct character which differs greatly from that found elsewhere on the continent. The present work brings together recent contributions to the taxonomy, distribution, and ecology of the entire West African freshwater crab fauna (Bott, 1955, 1959, 1964, 1969a, 1970a ; Monod, 1977, 1980 ; Cumberlidge, 1985a, 1987, 1991a, 1993a,b,c, 1994a,b, 1995a,b,c,d, 1996a,b, 1999 ; Cumberlidge and Clark, 1992 ; Cumberlidge and Sachs, 1989a, 1991) and presents new information on phylogeny and biogeography. The past ten years or so have seen the establishment of two new genera (#Potamonemus Cumberlide and Clark, 1992 and #Louisea Cumberlidge, 1994) and the description of a number of new species from West Africa... (D'après résumé d'auteur

Pressure Induced Changes in the Antiferromagnetic Superconductor YbPd2Sn

Low temperature ac magnetic susceptibility measurements of the coexistent antiferromagnetic superconductor YbPd2Sn have been made in hydrostatic pressures < 74 kbar in moissanite anvil cells. The superconducting transition temperature is forced to T(SC) = 0 K at a pressure of 58 kbar. The initial suppression of the superconducting transition temperature is corroborated by lower hydrostatic pressure (p < 16 kbar) four point resisitivity measurements, made in a piston cylinder pressure cell. At ambient pressure, in a modest magnetic field of ~ 500 G, this compound displays reentrant superconducting behaviour. This reentrant superconductivity is suppressed to lower temperature and lower magnetic field as pressure is increased. The antiferromagnetic ordering temperature, which was measured at T(N) = 0.12 K at ambient pressure is enhanced, to reach T(N) = 0.58 K at p = 74 kbar. The reasons for the coexistence of superconductivity and antiferromagnetism is discussed in the light of these and previous findings. Also considered is why superconductivity on the border of long range magnetic order is so much rarer in Yb compounds than in Ce compounds. The presence of a new transition visible by ac magnetic susceptibility under pressure and in magnetic fields greater than 1.5 kG is suggested.Comment: 5 pages, 6 figure

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362